 Primary open-angle glaucoma (POAG) is an idiopathic disorder in which the resistance to outflow through the trabecular meshwork gradually increases and the intraocular pressure (IOP) rises, causing irreversible damage to the optic nerve  POAG is the second most common cause of vision loss in the U.S.  Usually asymptomatic until advanced visual field loss has occurred; less than 50% of those with glaucoma are aware of their disease  Early diagnosis and referral of patients with suspected chronic glaucoma are essential to prevent ongoing damage to the optic nerve and further loss of visual field  IOP reduction, by medical or surgical means, has been demonstrated to delay or prevent disease progression at both the early and late stages of the disease  Acute primary glaucoma requires immediate referral to an ophthalmologist; chronic primary glaucoma requires routine referral Background Description  Glaucoma comprises a group of eye diseases that constitute the second most common cause of vision loss in the U.S.  The common feature of all forms of glaucoma is damage to the optic nerve. Raised IOP is the only modifiable risk factor  In 20% to 30% of cases, optic neuropathy and corresponding visual field loss develop despite an IOP that remains in the normal range (10-21 mm Hg) in a condition known as normal-tension or low-tension glaucoma. Conversely, individuals with a raised IOP may present no evidence of optic neuropathy  In glaucoma, early diagnosis and effective treatment to reduce IOP provide the best means of preventing damage to sight, as any visual loss that takes place cannot be reversed  POAG, the most common form of glaucoma, is an idiopathic disorder in which the resistance to outflow through the trabecular meshwork gradually increases and the IOP rises, causing damage to the optic nerve  The anterior chamber drainage angle is anatomically open  Secondary glaucoma develops from the presence of some other ocular or systemic condition and is less common than POAG
 Aqueous humor is secreted by the ciliary body and flows anteriorly into the anterior chamber. Normal outflow occurs through the trabecular meshwork and, to a lesser extent, via the uveoscleral route  The precise mechanism by which raised IOP damages the optic nerve is not known. It is believed that an abnormally high fluid pressure on the optic nerve head may cause death of nerve axons, possibly through an ischemic process  Optic neuropathy is associated with characteristic features of structural damage to the optic nerve and development of corresponding visual field defects  'Cupping' is the classical clinical finding in an optic nerve head that has been damaged by raised IOP. The diagnosis of glaucoma is made when the typical appearances of the optic disc are accompanied by corresponding visual field loss, initially affecting the peripheral fields  The terms primary congenital glaucoma and primary infantile glaucoma tend to be used interchangeably. Strictly defined, congenital glaucoma that manifests soon after birth is called neonatal glaucoma, while infantile glaucoma includes cases that develop in the first 3 years of life. Congenital glaucoma that develops from the age of 4 years is termed juvenile glaucoma  Chronic glaucoma is usually slow to progress and asymptomatic until advanced visual field loss has occurred  If POAG is present in one eye, the 5-year risk of developing the condition in the other eye is increased five-fold in comparison to patients who have no evidence of POAG in either eye  Approximately 20% of cases of chronic glaucoma are secondary to some other ocular or systemic condition, including neovascularization, trauma, and uveitis  In ocular hypertension, IOP is raised but there is no discernible damage to the optic nerve head and no visual field restriction; 20% of people with ocular hypertension, however, develop visual field defects within 5 years Epidemiology Incidence  A wide range of estimates exists for the incidence and prevalence of POAG, possibly due to differences in the age range and ethnic origin of populations studied  Annual incidence rate of POAG in a predominantly white population in the U.S. has been conservatively estimated at 14.5/100,000. Rates increased with age from 1.6/100,000 in the fourth decade of life to 94.3/100,000 in the eighth decade  Primary infantile glaucoma is the most common form of glaucoma in infancy, with an incidence of approximately 5 to 10/100,000 live births in the western world and a higher incidence in areas where consanguineous marriage is common Prevalence  Estimates of the overall prevalence of POAG range from 1,400/100,000 in a non-Hispanicwhite cohort in the U.S. to 6,800/100,000 in a predominantly African-Caribbean population study in Barbados  In various studies, the prevalence for those aged 40 through 49 years has been reported as 200 to 500/100,000 in non-Hispanic white persons, 500 to 1,300/100,000 in Hispanics, and 1,300 to 1,400/100,000 in black persons  For those aged 80 years or older, rates are 1,900 to 9,900/100,000 in non-Hispanic white persons, 12,600 to 21,800/100,000 in Hispanics, and 12,900 to 23,200/100,000 in black persons  U.S. research has found age-adjusted prevalence rates for POAG to be four to five times higher in black persons as compared with non-Hispanic white persons
Demographics
Age:
 Increasing incidence and prevalence of glaucoma with increasing age  Rare in patients younger than 40 years Gender:
 No gender difference for POAG  Primary infantile glaucoma affects more boys than girls in a ratio of 3:2
Race:  In the U.S., POAG is more prevalent in black and Hispanic populations and may occur at an earlier age than in white persons  Normal-tension glaucoma is more common in Japanese Americans
Genetics:
 Family history is a predisposing factor but the exact mode of inheritance remains unclear  No single Mendelian mode of inheritance has been described  First-degree relatives of individuals with POAG have an eight-fold increased risk of developing the condition as compared to the general population  A genetic contribution to the etiology of POAG is suspected, possibly involving the interaction of multiple genes and environmental factors  It is considered that a small proportion of POAG is attributable to single gene defects.
Chromosomal locations have been mapped of several genes that can independently cause the disease. Mutations of the myocilin gene have been shown to occur in a subset of families with a high incidence of juvenile-and adult-onset POAG 
Causes and risk factors Causes

Screening modalities
 Most cases of high IOP, glaucomatous optic discs, and visual field defects in adults are discovered by an optometrist during routine eye examination  Routine eye exams are recommended every 2 to 4 years from age 40 and every 1 to 2 years from age 65  For those at high risk, eye exams are recommended every 3 to 5 years from age 20, every 2 to 4 years from age 30, and every 1 to 2 years from age 65  Examination should include measurement of IOP and assessments of the optic disc, retinal nerve fiber layer, and visual function  Optometrists should refer patients to their primary care provider for secondary referral to an ophthalmologist
Primary prevention
Not applicable. 
Diagnosis
Diagnostic testing
 Snellen visual acuity test : visual acuity is not affected until late in the disease, but acuity should be recorded for a baseline  An ophthalmoscope is the most helpful tool available to the non-specialist physician for the diagnosis of glaucoma  The appearance of the optic disc should be recorded by photograph or drawing at initial assessment to allow future comparison  Slit lamp examination provides a stereoscopic view of the optic disc under high magnification and excellent illumination. The anterior segment structures can also be examined and a preliminary assessment made of the degree of openness of the anterior chamber  Tonometry and optic disc examination are the most useful tests in establishing glaucoma.
Tonometry is usually performed by an ophthalmologist or optometrist  Gonioscopy allows either direct or indirect visualization of the anterior chamber angle  Pachymetry measures central corneal thickness and is usually performed by a specialist.
Thin corneas have been shown to be a risk factor for open-angle glaucoma  Automated visual field testing is usually performed by an optometrist or ophthalmologist.
Physician Consultation  Immediate referral if signs of acute angle-closure glaucoma are present: red, painful eye with partially dilated, fixed pupil associated with reduced vision; headache; and a firm eye on palpation  Final diagnosis or exclusion of POAG is within the scope of eye specialists. In most states in the U.S., optometrists can prescribe antiglaucoma drops; chronic glaucoma may be referred to either an optometrist or an ophthalmologist  Patients with a raised IOP (22 mm Hg or higher), with or without abnormal optic disc head appearance or visual field abnormality, should be referred soon for ophthalmologic assessment. All individuals with optic nerve changes suggestive of glaucoma should be referred for evaluation, even if IOP is not raised  Patients with a relative afferent pupillary defect with or without visual field defects should be referred for ophthalmologic assessment  Patients who have asymmetric optic nerves (the physiologic cup within the optic nerve head of one eye being a different size than the cup in the other eye) should be referred for a glaucoma evaluation even if the IOP is normal  Provide the ophthalmologist with information on previous ocular history, significant past medical history, and concurrent medication and allergies Treatment Summary approach  The goal of treatment is to enhance the patient's health and quality of life by preserving visual function without causing unwelcome effects  IOP is the only risk factor that has proved amenable to treatment. IOP reduction has been demonstrated to delay or prevent disease progression both at the early and late stages of the disease, protecting the optic nerve and preserving the visual field  A target IOP range should be established for each patient based on a risk assessment and set at the level below which further optic nerve damage is unlikely to occur  Most commonly, the initial goal of treatment is to reduce IOP by 20% to 40%, although in some cases where there is evidence of severe optic nerve damage or other risk factors, a reduction of more than 40% may be targeted  The greater the pre-existing damage due to glaucoma, the lower the target IOP should be, and the target should be reset to a lower level if further deterioration occurs
Medical treatment
 Therapy for most patients with a new diagnosis of glaucoma commences with a singledrop treatment and the setting of a target IOP level  Monotherapy is preferred due to increased compliance, but different classes of ophthalmic treatments may be substituted or combined up to a point of maximal tolerated medical therapy  In practice, a combined approach to treatment of chronic glaucoma may be more effective in lowering the IOP and preventing glaucomatous progression than monotherapy because of a synergistic effect between therapeutic approaches
First-line therapies:
 Prostaglandin analog or β-blocker ophthalmic formulations, unless there are specific contraindications in the individual patient  Nonselective β-blockers include timolol , levobunolol (available in preservative-free formulation), and carteolol . The selective β-1 blocker, betaxolol , has fewer respiratory adverse effects and is favored for elderly patients Second-line therapies, or first-line therapies for patients in whom β-blockers are contraindicated:
 Ophthalmic α-agonists such as brimonidine or apraclonidine may be used short-term  Ophthalmic carbonic anhydrase inhibitors such as dorzolamide (available in combination with timolol) and brinzolamide Third-line therapies for patients who are intolerant of other ophthalmic treatments:
 Oral carbonic anhydrase inhibitors , such as acetazolamide or methazolamide . Long-term use should be avoided because of risk of systemic adverse effects  Ophthalmic pilocarpine is available in 1% to 6% formulations (also available in preservative-free preparations)
Surgical treatment
 If target IOP is not achievable with maximal tolerated medical therapy, trabeculoplasty or trabeculectomy must be considered. Drainage shunts may be required in refractory cases  Laser trabeculoplasty has been shown in various studies to provide a 20% to 30% reduction in IOP  Incisional surgical procedures are generally the most effective in lowering IOP but are only considered when benefits outweigh the risks of complications Laser surgery:
 Argon laser trabeculoplasty may be used as an adjunct to medical therapy or incisional surgery and is performed in the office  Selective laser trabeculoplasty is similar to argon laser trabeculoplasty but uses a neodymium:yttrium-aluminum-garnet (Nd:YAG) laser  Contact laser cyclophotocoagulation (CPC) uses an argon laser with a contact probe applied at the limbus to ablate the ciliary body and decrease aqueous production. Often used as a last resort after medication and incisional surgery have failed
Incisional surgical therapies:
 Trabeculectomy is the gold standard glaucoma filtration surgery. Should be considered when target IOP is not reached with medical or laser therapy. Should be considered if glaucomatous progression occurs despite reaching previous IOP target level  Treatment with antimetabolites such as 5-fluorouracil (5-FU) or mitomycin C (MMC) can decrease scarring following trabeculectomy and increase long-term success  Drainage implants and tube shunts are being used more frequently in cases of resistant glaucoma. Such devices channel aqueous from the anterior chamber through a long tube to an equatorial plate that acts as a base for a bleb to form  Several drainage devices with varying design details are available. Implants have been associated with around 50% failure rate at 5 years. Excessive fibrosis around the bleb appears to be a major cause of long-term failure in glaucoma drainage devices  Endocyclophotocoagulation is similar to contact CPC but instead uses a probe that combines an argon laser with a fiberoptic scope to directly visualize and ablate the ciliary body. Usually performed at the time of cataract extraction
Other forms of glaucoma
Normal-tension glaucoma:
 Limited available evidence for a beneficial effect of medical or surgical treatment is weak but suggests that lowering IOP using standard glaucoma treatments might help patients whose field loss is progressing despite normal IOP 
Medications
Prostaglandin analogs β-blockers (ophthalmic) α-adrenergic agonists Carbonic anhydrase inhibitors (ophthalmic) Carbonic anhydrase inhibitors (oral) Pilocarpine
Non-drug treatments
Argon laser trabeculoplasty Selective laser trabeculoplasty Trabeculectomy Drainage implants and tube shunts
Special circumstances
Very elderly, unwell patients may not undergo significant glaucomatous progression in their lifetime and may suffer considerable adverse effects from medical treatment. In consultation with the patient, it may be preferable to monitor the condition without treatment.
Comorbidities
Coexisting disease:  Coexisting bronchial asthma, severe COPD, overt heart failure, and heart block will preclude the use of topical β-blockers because of systemic absorption of the drug  Arthritis or a previous stroke may result in poor compliance if patients have difficulty administering drop therapies
Coexisting medication:
 Patients who are prescribed treatment with both an oral and topical β-adrenergic blocking agent should be observed for potential additive effects of β-blockade, both systemic and intraocular  Use of α-agonist drugs, such as brimonidine or apraclonidine, is contraindicated with concurrent MAOI use  Concurrent topical or oral steroid use may increase IOP and make control more difficult Special patient groups:  Therapy regimens for very elderly, unwell, or incapacitated patients should be made as simple as possible to limit adverse effects and improve compliance  Once-a-day treatment regimens or surgical options may be more appropriate in elderly patients who rely on others to administer drops or where compliance is a problem  Younger patients, those with more severe disease, or those with greater risk factors for glaucomatous damage should be treated more aggressively, with lower target IOP levels
Patient satisfaction/lifestyle priorities
Bilateral visual field loss secondary to glaucoma may affect the patient's legal ability to hold a commercial or personal driver license.
Follow-up
 Follow-up is essential to monitor IOP and assess compliance, progression of optic neuropathy and visual field loss  Frequency of follow-up is dependent on the stability of the disease  Target IOP should be reset to a lower level if further deterioration occurs Plan for review  When treatment is commenced or changed, review is usually 6 to 8 weeks later  If the IOP level has responded well to topical treatment and the visual field and optic disc appearance are stable, follow-up may be every 3 to 4 months  Visual field and optic disc analysis should be performed at least yearly in glaucoma patients who have normalized pressures to optimize the detection of glaucomatous progression
Ocular hypertension:
 Although there is agreement that patients with ocular hypertension require regular follow-up, the value of treating these patients to lower their IOP is uncertain, as only a subset will ultimately develop visual field abnormalities or glaucomatous optic neuropathy  Ophthalmic preparations that are indicated for POAG may also be used for treating ocular hypertension Prognosis  Optic nerve damage that has already taken place at the time of diagnosis is irreversible  Early diagnosis and effective medical and/or surgical treatment to reduce IOP provide the best means of preventing further damage to sight  Some glaucoma patients with normalized pressure will continue to lose visual field, and the pressure may have to be reduced even further by altering medical treatment or proceeding to surgery  The majority of patients with ocular hypertension may never develop glaucoma
Factors affecting prognosis:
 Prognosis depends on the extent of glaucomatous damage at presentation, level of the presenting IOP, age of the patient, and IOP level after medical or surgical treatment  Elderly patients with moderate glaucomatous damage at presentation and slow progression because of suboptimal IOP control may not notice any decreased visual function over their lifetime  In younger patients and black patients, glaucoma may progress more quickly and be more difficult to control  In childhood glaucoma, permanent visual loss may arise as a result of amblyopia , which can develop in addition to and secondary to optic neuropathy. Consequently, amblyopia must be treated aggressively  Risk of conversion from ocular hypertension to glaucoma is increased by older age, larger vertical or horizontal cup-disc ratio, higher IOP, greater visual field pattern standard deviation, and thinner central corneal measurement 
Resources
Summary of evidence
Evidence
The use of topical β-blockers in the surgical management of POAG is associated with significantly greater disease control than observation alone as the primary treatment.
 An RCT compared laser trabeculoplasty plus topical betaxolol hydrochloride versus no initial treatment in 255 patients with newly detected POAG or pseudoexfoliation glaucoma, previously untreated. After 6 years, there was a significant reduction in the number of people in the laser trabeculoplasty (plus topical betaxolol hydrochloride) group with progression of glaucoma compared with control (58/129 or 45% vs 78/126 or 62%, respectively ( P =.007), and the average time to progression was longer in the treated group. [5] Level of evidence: 2
Comparisons between surgical and laser treatments have found that both therapies are effective. However, some studies suggest that surgical trabeculectomy is superior to other therapies. There is limited evidence that latanoprost is superior to timolol in reducing IOP in patients with POAG.
 An RCT of 267 patients compared treatment with timolol 0.5% twice daily versus latanoprost 0.005% in the morning versus latanoprost 0.005% in the evening. It found that latanoprost applied once daily in the evening was superior to timolol in reducing IOP. [1] Level of evidence: 2  A second RCT of 268 patients compared treatment with latanoprost 0.005% once daily versus timolol 0.5% twice daily. This study found that there was a significantly greater decrease in IOP with latanoprost, which was also relatively well tolerated, compared with timolol.
[2] Level of evidence: 2
There is limited evidence that brimonidine is an effective alternative to topical β-blockers as a medical therapy for POAG.
 Combined data from an RCT involving 926 patients concluded that brimonidine showed similar efficacy to timolol and had a relatively low rate of ocular allergy. [8] Level of evidence: 3  An RCT treated 206 adults with either brimonidine 0.2% or betaxolol 0.25% for a 3month period. Brimonidine was well tolerated and clinically and statistically more effective than betaxolol 0.25% at lowering IOP during both peak ( P = .004) and trough ( P < .001) IOP measurements in patients with OAG and ocular hypertension. [9] Level of evidence: 3
The combination of dorzolamide-timolol is as effective as latanoprost.
 A prospective, randomized, crossover comparison study of 53 patients, 39 with POAG and 14 with ocular hypertension, showed that after 6 months of therapy, the dorzolamidetimolol fixed combination is as effective as latanoprost in lowering IOP. [4] Level of evidence: 3
There is limited evidence that topical dorzolamide is an effective alternative to topical β-blocker therapies in the medical treatment of POAG.
 An RCT of 523 patients compared topical treatment with dorzolamide 2% three times a day versus timolol 0.5% twice daily versus betaxolol 0.5% twice daily in patients with OAG or ocular hypertension. Patients were followed up for 1 year. Results confirmed treatment with dorzolamide was as effective as betaxolol at lowering IOP. None of the significant adverse effects found with oral carbonic anhydrase inhibitors were found to occur with topical dorzolamide. [ There is some evidence that surgical trabeculectomy is effective as an initial therapy for POAG.
 An RCT of 116 patients with POAG compared surgical trabeculectomy (followed by medical treatment when indicated) versus medical treatment (followed by trabeculectomy when medical treatment did not work). This study found that initial trabeculectomy significantly reduced both IOP and visual field loss compared with medical treatment, although there was no significant difference in visual acuity with either treatment. [11] Level of evidence: 1  A large, multicenter trial involving 607 people newly diagnosed with POAG, pigmentary glaucoma, or pseudoexfoliation glaucoma compared surgical trabeculectomy (with or without 5-FU) versus medical treatment as initial treatments. It found no significant difference between groups in visual field loss after 5 years, and progression of visual field loss was similar with both treatments. Loss of visual acuity was greater in the surgical group at 5 years, but the significance of this difference was not reported. Both treatments reduced IOP, but the reduction was significantly greater in those patients treated with surgical trabeculectomy. [12] Level of evidence: 1
The use of adjunctive medications increases the success rate for surgical interventions.
 A systematic review of 9 trials of questionable methodology including 614 patients treated with trabeculectomy, randomly selected to receive postoperative 5-FU versus placebo or no injections, found that the use of higher dose postoperative 5-FU reduces the risk of surgical failure in eyes that have undergone no previous surgery and in eyes at high risk of failure. [13] Level of evidence: 2  A systematic review of 11 trials including 698 patients treated with trabeculectomy with or without intraoperative MMC found that treated patient had a reduced risk of trabeculectomy failure in eyes that had previously failed surgery (RR = 0.32; 95% CI 0.20-0.53) and in patients new to surgery (RR = 0.29, 95% CI 0.16-0.53). [14] Level of evidence: 1
